Anjali P B et al /J. Pharm. Sci. & Res. Vol. 11(2), 2019, 661-666

ISSN:0975-1459
Journal of Pharmaceutical Sciences and Research
www.jpsr.pharmainfo.in

Recent Approaches for Seizure Activation Therapy

Anjali P B, Jawahar Natarajan*, Arun Radhakrishnan
Department of Pharmaceutics
JSS Collage of Pharmacy, Ooty, Tamil Nadu – 643001, India
JSS Academy of Higher Education & Research, Karnataka, India

Abstract

Epilepsy is a standout amongst the most well-known and genuine confusion of the focal sensory system (CNS). With an expected occurrence of 34 to 76 new cases for every year per 100,000 individuals, epilepsy influences around 70 million individuals around the world. Epilepsy influences the extra shrouded weight of criticism, segregation and preference against patients in the school, home, network and working environment. Individuals having epilepsy were experiencing enthusiastic pain, reliance on family, social disengagement, poor business openings, and individual damage. Epileptic seizures having sway on patient's life quality, expanded danger of damage, passing, and financial and instructive impediment. Generous substantial and mental comorbidities are related with epilepsy, including damage, suffocating, despondency, nervousness, and high suicide rates. Uncontrolled seizures and the movement of epilepsy can bargain memory, cognizance, and endocrine capacity and can introduce an expanded danger of horribleness. Mortality in patients with epilepsy, including "sudden unexplained demise in epilepsy" (SUDEP), is multiple times the rate seen in the overall public. The objective is to convey the medication to the mind in amounts adequate to take out seizures without causing unfriendly impacts. In 30% of the cases, sufferers of epilepsy can't be cured because of the portion required to stifle seizures causing unfriendly symptoms. This review discuss about new approaches to overcome the problems associated with current treatment of epilepsy.

Key Words : Epilepsia, epilepsy, seizure-activation, anti-epileptics, conventional, nano-technology

INTRODUCTION

Epilepsy is a group of disorders of the Central nervous system (CNS) characterized by brief episodes (seizures) of loss or disturbance of consciousness, with or without the presence of characteristic body movements (convulsions). These episodes of symptoms are unpredictable and their frequency might be variable. The exact origin of epilepsy recognized from the dawn of history as 'Disease of lightening' which is described by JH Jackson over a century ago.

Epilepsy is characterized by the International League Against Epilepsy (ILAE) as "a confusion of the mind portrayed by a continuing inclination to produce epileptic seizures and by neurobiological, intellectual, mental and social outcomes of this condition. The meaning of epilepsy requires the event of somewhere around one epileptic seizure." (Fisher et al., 2005).

Epilepsy has been classified into different types, major types are described below :-

I. Generalized seizure :-
   a) Generalized tonic clonic seizure (GTCS) :
      Characterized by unconsciousness, tonic spasm of all body muscles and clonic jerking followed by prolonged sleep and supervision of all CNS functions.
   b) Absence seizure :
      Loss of consciousness without muscular pain.
   c) Atonic seizure :
      Unconsciousness with relaxation of body muscles due to excessive inhibitory discharge.
   d) Myoclonic seizure :
      Momentary contraction of limb muscles or whole body.

II. Partial seizure :-
   a) Simple partial seizure (SPS) :
      Which is lasts for 30 sec to 1 minute, then convulsions are confined to a group of muscles or localized sensory disturbances depends on the area of cortex involving the epilepsy.
   b) Complex partial seizure (CPS) :
      The seizure center is situated at the fleeting flap. Befuddled conduct, purposeless developments and enthusiastic changes which is goes on for 1-2 minutes alongside hindrance of cognizance.
   c) Simple partial or complex seizure secondarily generalized :

Halfway seizure happens first and advanced into summed up tonic clonic seizure with loss of awareness [58].

The principle objective of treatment for epileptic patient is no seizures with next to zero reactions. Be that as it may, because of specific inconstancies in clinical introduction and accessible assets, treatment ought to be very individualized and differ generally [1]. Development of epilepsy treatment, the quality of life of patients suffering from the same remains very poor. The major problems are development of drug resistance and reoccurrence of seizure after minimizing the medication [2].

In the treatment of epilepsy, none of the anti-epileptic drug (AED) has shown the maximum effectiveness and all AEDs having their own set of adverse side effects. ADEs are selected based on some considerations of side effects, ease of administration, cost effectiveness and knowledge of medical practitioner about the drug [3]. Most of the anti-epileptic drugs are given through either orally or intravenously. Near about 40% of patients develops drug resistance in the last stage of medication [4].

Medication safe epilepsy, likewise called as obstinate epilepsy or stubborn epilepsy, is characterized as disappointment of sufficient preliminaries of two endured, fittingly picked and utilized antiepileptic sedate timetables (regardless of whether as mono-treatment or in blend) to accomplish continued seizure opportunity. This explanation of drug resistance proves that the epileptic patients needs expert care with single or combination therapy [5]. There is an opportunity of patient may encounter total protection from AED treatment or might be esteemed just somewhat responsive if seizures are diminished in recurrence or power however not dispensed with [6].

The reason for epilepsy is totally obscure. The word epilepsy does not demonstrated any data about the causes or seriousness of the seizures, at times of epilepsy are actuated by hereditary variables, however it can likewise results due to mind wounds brought about by hits to the head, stroke, diseases, high fever or tumors. Be that as it may, not every person who has genuine head damage will create epilepsy. It has been seen that hereditary qualities assumes a critical job in numerous reasons for epilepsy in youthful youngsters, however it very well may be a factor for individuals of all ages [7].

The commonness of epilepsy in people fluctuates populace to populace, however no place is it under 3 cases for every 1000 of populace and in a few areas is as high as 40 cases for each 1000 of populace. In the UK, the commonness of epilepsy is evaluated as 9.7 cases per 1000 of populace, and the occurrence is assessed at 0.51 cases per 1000 of populace for every year [8].

HISTORY

The term 'Epilepsy' originated from the Ancient Greek word 'Epilepsia'; which means 'to take hold of' or 'to seize' which in turn was combined form 'epi' means upon and 'lambanein' means to take.

The oldest details about the epilepsy is on a Babylonian table in the British Museum and it is a chapter from Babylonian textbook of medicine containing 40 tablets used approximately in 2000 BC [9]. Old Romans trusted that epilepsy originated from devils, and it was infectious by contacting or being inhaled on by an individual with epilepsy. On the off chance that this would happen, individuals would spit to dispose of the devil. Since they thought epilepsy was infectious, individuals with epilepsy would need to live alone [10].

The Babylonian named it 'The Sacred disease'. Hippocrates believed that epilepsy was nit a sacred disease and it is a disorder of brain – it was a revolutionary view. He recommended physical treatments for the disease and he stated if the disease become chronic, can't cure the disease.

In 19th century, the concept epilepsy became widely accepted in Europe and North America. Sir Charles Locock, introduce Bromide as a world's first effective anti-epileptic drug in 1857. In the same year a hospital for 'paralyzed and epileptic' was established in London. Hughlings Jackson, a nervous system specialist suggested that the seizure due the sudden electro-substance releases of vitality in the mind character of the seizures relying upon the area and capacity of the seat of the releases at 1873.

Hans Berger in 1920s developed electroencephalograph (EEG) – brainwaves while working in Germany and it has important application in the field of epilepsy. EEG revealed the presence of electric discharges in the brain and also showed different patterns of brainwave discharges associated with different seizure types. The EEG helped to locate the site of seizure discharges and expanded the possibilities of neurosurgical treatments.

Amid the primary portion of this century the principle drugs for the treatment of epilepsy were phenobarbitone and phenytoin in the time of 1912 and 1938 individually. The majority of the advances in created economies are of next to zero pertinence to the 80% of individuals with epilepsy who live in creating nations. The International League Against Epilepsy, an overall expert association, was established in 1909 and is developing quickly, with 60 nations. The International Bureau for Epilepsy, the equal lay association, was established in the time of 1962 and is additionally quickly growing, with 50 national parts.

In 1997, these two associations united with the World Health Organization in the Global Anti-Epilepsy Campaign went for enhancing aversion, treatment, care and administrations for those with epilepsy and raising open attention to the turmoil and its adequacy [11].

PATHOPHYSIOLOGY OF EPILEPSY

Seizures are paroxysmal appearances of the cerebral cortex. A seizure happens when a sudden awkwardness happens between the excitatory and inhibitory powers inside the system of cortical neurons. The physiology of a seizure scene can be distinguished in a temperamental cell film or its encompassing or contiguous supporting cells. The seizure starts from the dark matter of cortical or sub-cortical territory. At first few neurons will fire strangely. After that ordinary film conductance and inhibitory synaptic current breakdown and abundance volatility spread either locally to deliver a central seizure or all the more broadly to create a summed up seizure. This beginning proliferates by physiologic pathways to include neighboring remote regions [12].

Irregularity in potassium conductance, an imperfection in the voltage gated particle channels, or a lack in the layer ATPases connected to particle transport may cause neuronal film flimsy and it at last causes seizure. Certain synapses, for example, acetyl choline, glutamate, norepinephrine, aspartate, histamine, corticotropin discharging factor, purines, peptides, cytokines and steroid hormones improves the sensitivity and spread of neuronal action, while gamma-amino butyric corrosive (GABA) and dopamine restrain neuronal movement and engendering.

Amid a seizure, the blood stream request to the mind increments to steal away carbon dioxide (CO2) and to bring substrate for metabolic movement of the neurons, as the seizure drags out, the cerebrum experiences more ischemia that outcomes in neuronal annihilation and mind harm. Change in a few qualities might be connected to a few sorts of epilepsy. Qualities that code for protein subunits of voltage-gated and ligand-gated particle channels have been related with the summed up epilepsy and puerile seizure disorders [7].

Mechanism of epileptogenesis :

a) GABA : -
   - Reduction in the presence of GABA in microgyric cortex
   - Reduced benzodiazepine receptor binding in medial thalamic nucleus - mesial temporal lobe epilepsy
   - Reduced benzodiazepine receptor density in CA1 region- hippocampal sclerosis
   - Reduced GABA levels and GAD activity

b) Glutamate :-
   - Upregulation of hippocampal ionotropic glutamate receptors- temporal lobe epilepsy
   - Presence of Anti-gluR3 antibodies
   - Increased plasma glutamate levels

c) Sodium channel :-
   - Mutation voltage-gated Na^+ channel - generalized epilepsy with febrile seizures

d) Potassium channel : -
   - Mutation voltage-gated K^+ channel

e) Calcium channel :-
   - Reduced Acetylcholine - mediated Ca^{2+} flux

f) Increased membrane excitability [13]

SEIZURE ACTIVATION

In this system, a dormant antecedent medication is initiated by a substance discharged at the seizure center. This results in a highly specific concentration of drug at the seizure focus, with little drug effect at other brain or systemic sites. One drug utilizing this strategy with the phosphono group attached, the drug is without effect. When a seizure occurs, elevated activity of the enzyme phospholipase-A2 cleaves the phosphono moiety and generates locally high concentrations of drug. The extent to which a seizure needs to be underway before activating a drug, as well as intrinsic characteristics of the drug itself may determine its utility in real clinical situations [14].

TREATMENT

Anti-seizure medications:

Anti-epileptic drugs (AEDs), also referred to as Anti-seizure Drugs (ASD), are intended to keep the event of seizures in patients with epilepsy, and are most common and effective way to suppress seizures. AEDs don't cure epilepsy, but instead work to reduce the amount of electrical activity in the brain, stopping seizures before they happen. There are more than 20 different varieties of anti-seizure medications, each with a different set of potential benefits and side effects, so it's important to consult a doctor about which medications are best for the type of seizures they have. And should not surprise if the prescription takes a few adjustments in medications and/or dosages. Most people have to try more than one medication before they find what works best for them.

Table 1: Anti-epileptic drugs, their mechanism of action, clinical uses and adverse effects.

Drugs	Mechanism of action	Clinical uses	Adverse effects
Phenobarbital	GABA facilitatory, GABA-mimetic, antiglutamate, Ca^{2+} entry reduction	Generalized and partial seizures (ineffective for absence seizures), status epilepticus	Sedation, coarsening of facial highlights, dysarthria, laziness, Dupuytrens' contracture, osteomalacia, diminished charisma, psychological issues, distractability (in youngsters), hyperkinesia (in kids), teratogenicity, skin rashes, a sleeping disorder (in kids), touchiness (in kids), hepatoxicity.
Phenytoin	Na^{+} channel blocker	Generalized tonic-clonic seizures, partial seizures, status epilepticus, (ineffective against myoclonic and absence seizures)	Diplopia, ataxia, nystagmus, hirsutism, skin rashes, Dupuytren's contracture, Stevens–Johnson syndrome, agranulocytosis, aplastic anemia, coarsening of facial features gingival hyperplasia, hepatoxicity, teratogenicity
Ethosuximide	Ca^{2+} blocker	Absence seizures	Gastrointestinal changes, headache, mood changes, drowsiness, aplastic anemia lethargy, visual changes, agranulocytosis
Carbamazepine	Na^{+} channel blocker	Generalized tonic-clonic seizures, partial seizures, status epilepticus, (ineffective against myoclonic and absence seizures)	Diplopia, headache, dizziness, skin rashes, ataxia, agranulocytosis, weight gain, nystagmus, hyponatremia, aplastic anemia, osteomalacia, hepatoxicity, Stevens–Johnson syndrome, teratogenicity
Valproic acid	Na^{+} channel blocker, weak attenuation of Ca^{2+} mediated T current, augmentation of release of GABA	Generalized and partial seizures	Tremor, dyspepsia, weight gain, diarrhea, hair loss, peripheral edema, pancreatitis, agranulocytosis, polycystic ovaries, thrombocytopenia, Stevens–Johnson syndrome, hepatoxicity, teratogenicity
Felbamate	positive modulator of GABA, blocker of NMDA receptors	Lennox-Gastaut syndrome (Severe and/or refractory epilepsies)	Anorexia, insomnia, weight loss, headache, ataxia, dizziness, aplastic anemia, skin rashes, hepatoxicity
Vigabatrin	GABA potentiation	Generalized and focal seizures with focal onset	Headache, dizziness, depression, fatigue, permanent visual-field deficits
Gabapentin	Ca^{2+} blocker ($\alpha 2\delta$ subunit)	Adjunct therapy for partial seizures (ineffective against absence and myoclonic seizures)	Drowsiness, fatigue, dizziness, hyperactivity (in children), ataxia,weight gain
Pregabalin	Ca2+ blocker ($\alpha 2\delta$ subunit)	Adjunct therapy for partial seizures	Weight gain, dizziness, somnolence, headache, peripheral edema, asthenia, ataxia
Lamotrigine	Na+ channel blocker	Adjunct therapy for generalized and partial seizures , Lennox-Gastaut Syndrome	Dizziness, diplopia, headache, sedation, ataxia, Stevens-Johnson syndrome, skin rash
Topiramate	Multiple (GABA potentiation, glutamate [AMPA] inhibition, sodium and calcium channel blockade)	Adjunct therapy for generalized and partial Seizures	Cognitive problems, kidney stones, anorexia, word finding difficulty, paresthesias, weight loss, acute angle closure glaucoma
Tiagabine	GABA potentiation	Adjunct for partial seizures (ineffective against absence seizures)	Dazedness, torpidity, tremor, apprehension, enthusiastic changes
Vigabatrin	GABA potentiation	Refractory partial seizures (ineffective against absence and myoclonic seizures)	Drowsiness, tremor, dizziness, ataxia, lethargy, insomnia, weight gain, psychosis and depression, visual field defects and blindness, Irritability and hyperactivity (in children
Oxcarbazepine	Na+ channel blocker	Generalized tonic-clonic seizures, partial seizures, (ineffective against absence and myoclonic seizures)	Laziness, migraine, wooziness, diplopia, weakness, hyponatremia, GI trouble, skin rash, Stevens-Johnson disorder
Zonisamide	Na+ channel blocker	Generalized and partial seizures	Sedation, dazedness, cerebral pain, GI misery, skin rash, aplastic iron deficiency, agranulocytosis, kidney stones, weight reduction
Rufinamide	Na+ channel blocker	seizures in Lennox- Gastaut syndrome	Fatigue, loss of appetite, vomiting, somnolence, aggravated seizures, headache, status epilepticus
Lacosamide	Improved moderate inactivation of voltage gated Na+ channels	Focal and generalized seizures with focal onset	Dizziness, diplopia, headache, nausea
Eslicarbazepine	Na+ channel blocker	Focal and generalized seizures with focal onset	Tiredness, impaired coordination, rash, hyponatraemia dizziness, gastrointestinal disorders such as diarrhoea, nausea and vomiting
Perampanel	Glutamate (AMPA) opponent	Use for focal and generalized seizures with focal onset	Dizziness, falls, somnolence, irritability, ataxia, severe changes in mood and behaviour including aggression, hostility, anger, homicidal ideation, threats.

Epilepsy surgery:

If the seizures can't be controlled by medication alone, and having a clear diagnosis of specific seizure type and disorder, the doctor may suggest surgery. In epilepsy surgery, doctors identify the area of the brain housing the abnormal tissue where seizures are originating from and remove it. Before making the decision to have surgery though, it's important to weigh the risks against the potential rewards, as it's not guaranteed that the procedure will be able to completely control seizures.

Vagus nerve stimulation:
The vagus nerve stimulator (VNS), a device implanted in the chest under the skin, helps to reduce the number of seizures by sending regular electrical signals to stimulate the vagus nerve, a cranial nerve that carries important signals from the body to the brain. The VNS works both automatically and manually – patients can "turn it on" if they feel like they're about to have a seizure. It can be oftenly used with AEDs.

Ketogenic diet:
The ketogenic diet is a high-fat, low-carbohydrate plan that forces the body to burn fat for energy instead of glucose, which has been shown to help reduce seizures in some people with epilepsy. Doctors usually prescribe a ketogenic diet to kids who haven't had success in managing their seizures with medication alone. The ketogenic diet can help reduce seizures in adults, too, but most people aren't able to stick to it. And because this diet is so restrictive and specific, it can be tough to follow, so it should only be administered under the guidance of a physician and/or nutritionist.

Lifestyle changes:
While lifestyle changes alone can't control seizures, they are an empowering way to gain control over condition outside of the doctor's office. Getting enough sleep and regular exercise, and avoiding epileptic triggers such as smoking, alcohol and flashing lights, are all easy ways for you to manage your condition at home. Keeping a seizure diary to help you track triggers and seizure experiences is also a great tool for managing condition [15].

TREATMENT CHALLENGE:

Blood brain barrier
The cerebrum is shielded from the poisonous substances by the nearness two hindrances; Blood Brain Barrier (BBB) and Blood Ceribro Spinal Fluid Barrier (BCSFB). The "blood mind hindrance" was first authored by Lewandowsky in 1990. The structure of BBB is isolated into two segments: endothelial or slender obstruction and ependymal boundary. Blood brain barrier approximately 5000 folds greater than blood ceribro spinal fluid barrier [16]. Restricted entry of drug through BBB and its reduced bioavailability are the major challenges in the treatment of epilepsy. However only small molecules, both lipid soluble and molecules with molecular weight of 400-600Da diffuses through BBB. Same time, small molecules either water soluble or with molecular weight of 400-600Da are poorly transported through BBB [17]. Optimum transportation of compound across BBB can be achieved when the compound is unionized, having log P value around 2, molecular weight less than 400Da and not more than 8-10 hydrogen bonds [16]. In addition to physical barrier, there is a selective metabolism driven barrier which reflects the presence an function of several receptors, ion channels and protein transport [18].

Limitation with AEDs:
Presently accessible antiepileptic drugs has constrained adequacy, and their negative effects on their utilization and causes troubles in patient administration. Antiepileptic medications can give just to the symptomatic alleviation of seizures and have no impact on the epileptogenesis [19]. The long haul utilization of antiepileptic drugs is constrained because of their unfavorable impacts, withdrawal indications, malicious communications with different medications and monetary weight, particularly in creating nations [20].Anti epileptic drugs, their mechanism of action, clinical uses and adverse effects are given in table 1. [21-31]

NANOTECHNOLOGY TO MINIMIZE PROBLEMS

Liposomes:
Liposomes are unicellular or multicellular phospholipid vesicles that enclose a central aqueous compartment [32]. Liposomes are most investigated AED delivery system because of their ability to encapsulate the drug, biocompatibility and biodegradability [33]. The ability of altering their dimensions, membrane fluidability and surface characteristics made liposomes as a ideal nano carrier. Some reports states that there is enhanced bioavailability of drugs across the membrane and reduced enzymatic degradation by the use of liposomal carrier [34]. Half-lives of liposomes can be increased through vesicle size reduction, enhanced surface hydrophilicity or by the usage of polyethylene glycol (PEG) or glycolipid [35]. Some of the AED like valproic acid, superoxide dismutase, GABA and amiloride are in the preclinical stage of development and are expected to open new opportunities for the drug delivery to brain [36].

Polymeric nanoparticle:
Polymeric nanoparticles are biodegradable and biocompatible and they having size ranges from 10 to 1000nm. Polymeric nanoparticles can be utilized for the diverse techniques for nanomaterial medicate conveyance. Due to their safety and biocompatibility, USFDA approves use of poly (lactic-co-glycolic acid) (PLGA) based nanocarrier in humans. The potential degradation of PLGA in the body can be utilized to make them effective and it can be achieved by changing the copolymer ratio [37]. Medication stacked in the polymeric NP are discharged at the focused in the vicinity through mix of dissemination and polymeric corruption. Medication emptying proficiency of polymeric NPs differs from hours to month which relies upon medication – polymer proportion, atomic weight and compound arrangement of polymer [36]. Polymeric nanoparticles having some advantages over liposomes like ease of preparation, greater stability, increased storage potential and potential for their continuous and controlled release of drug for longer period of time. Same time polymeric nanoparticles and liposomes having disadvantages of rapid clearance from blood plasma due to opsonisation [38].

Polymeric nanospheres and nanosuspension:
Nanospheres are thick polymeric material with in a medication can be scattered and that can be set up by microemulsion polymerization process [39]. Medication stacked nanosuspension having crystalline medication molecule settled by utilizing non ionic surfactants or by utilizing blend of lipids [59]. Nanosuspension having focal points like straightforwardness, high medication stacking limit and appropriateness of medication to CNS conveyance. Polymeric nanospheres and nanosuspension having potential for surface alteration through compound change which give enhanced pharmacokinetic control and are appropriate entanglement of medication atom [40].

Solid lipid nanoparticles (SLN):
SLNs are alluded as new age lipid emulsion in which fluid lipid has been supplanted with strong lipid. A few examinations on SLN referenced that it very well may be administrated through a few courses like, oral, parentral, rectal, ophthalmic and topical courses which serves to controlled conveyance and upgraded bioavailability of ensnared medication [41,42,43]. Strong lipid nanoparticles are physiological lipid based conveyance framework which offers physical strength, security from corruption, simplicity of readiness and lower lethality. SLN forces lower danger because of their extraordinary properties like little size, extensive surface territory, high medication stacking and stage communication. SLNs having the capacity to enhance the proficiency of pharmaceuticals, nutracueticals and different materials [44]. SLNs has been produced as an elective medication conveyance framework for liposome and NPs. It is by all accounts a promising conveyance framework for the treatment of epilepsy as a result of the favorable circumstances as far as harmfulness, creation, achievability and versatility [45]. SLN might be an elective medication conveyance framework for the organization of

atoms to the cerebrum with delayed discharge profile and enhanced remedial impact in the treatment of epilepsy [46].

Nanostructured lipid carrier (NLC):

NLCs are second era of lipid nanoparticles which can be preared by mixing strong lipids and fluid lipids. NLC represents the latest innovation, researchers prefers them over SLN because NLC avoids lipid recrystallization [47]. NLC preferred over any other lipid nanoparticle due to their limitation like low loading capacity and drug expulsion during storage [48]. NLCs having several advantages similar to SLN like use of bio-compactable lipids, controlled delivery of drug from carrier, can be produced large scale at economical cost and protects drug from biochemical degradation. NLCs are classified into three types based on their nanostructure; 1. Imperfect type. 2. Multiple O/F/W type and 3. Amorphous type. Imperfect type of NLC can be set up by blending distinctive strong lipids and fluid lipids which ascend to flaws and thereby improving medication stacking. The Multiple O/F/W contains oil nanocompartment encapsulated with solid lipid. This can be prepared by lipid-lipid precipitation method. In this drug is either loaded or dissolved in the oil compartment. Amorphous type can be prepared by controlled mixture of special type of solid lipid and liquid lipid. NLC can be administrated via several routes [49].

Nanoemulsions (NE):

Nanoemulsions are heterogeneous medication conveyance framework comprises of oil, water and surfactant with bead estimate in the scope of 10-100nm [50]. Nanoemulsion can be easily prepared by spontaneous emulsification. They provide improved solubility and stability of loaded drug material [51]. It is an effective drug transport system shows improved rate of absorption, rapid penetration of drug molecule, reduced toxicity, decreased irritation, protection from degradation like oxidation and hydrolysis and administration through multiple routes such as topical, transdermal, parentral, ocular, pulmonary, nasal and oral [52,53,54,55]. The major advantage of NE with drug, that can be easily passes through the BBB even with drugs having reduced bioavailability. Nanoemulsion can be used to deliver both hydrophilic and lipophilic drugs [56]

Magnetic nanoparticles (MNP):

MNPs having potential for the powerful and site explicit conveyance of remedial specialists. The organic and clinical utilization of MNPs are recommended before three decades [32]. MNPs having significant attention towards targeting therapy because of their characteristic modulation type controlled by an external magnetic field which can able to give precise output like controlled and sustained drug release and transportation across the tissue which helps to minimize the toxicity of other tissues [57]. MNPs mainly consist of three ferromagnetic elements such as cobalt (Co), nickel (Ni) and iron (Ne). The application of MNPs depends on their preparation process.

CONCLUSION

In the treatment of epilepsy, ordinary treatment ends up not so much successful because of its diminished bioavailability, portion related symptoms and medication obstruction. Other enemy of epilepsy treatment like cerebrum medical procedure or vagus nerve trigger (VNS) implantation are pricey medications and its needs high innovation and propelled gear, with the goal that every single epileptic patients can't manage the cost of that. In this way there is a need of improvement of new medication conveyance frameworks for these epilepsy sufferers, that is restorative yet not lethal and furthermore can be available and reasonable by each patient everywhere throughout the world.

Nanotechnology is quickly blasting examination territory which gives trust in the treatment of different issue including CNS sicknesses. The capacity to cross the BBB and the objective explicitness is by all accounts the significant obstacles for the accomplishment of AEDs in pharmacotherapy. Utilizations of nanotechnology-based medication conveyance frameworks to treat epilepsy will be a promising answer for their impediments.

Acknowledgement

The authors would like to thank Department of Science and Technology – Fund for Improvement of Science and Technology Infrastructure in Universities and Higher Educational Institutions (DST-FIST), New Delhi for their infrastructure support to our department.

REFERENCES

[1] Mallik Angalakuditi, Nupur Angalakuditi, *Neuropsychiatric Disease and Treatment*, 2011, 7, 585–597
[2] De Rosa, G. Salzano, G. Caraglia, M., Abbruzzese, A., *Curr. Drug Metab.*, 2012, 13 (1), 61-69.
[3] French, J.A, Kanner, A.M., Bautista, J., et al, *Neurology*. 2004, 62(8), 1261–1273
[4] Bauer, B., Schlichtiger, J., Pekcec, A., M.S, 2011.
[5] S. Abramovici, A. Bagic, 2016, 138,
[6] C. Lee Ventola, ,M.S., *P&T*, 2014, 39, 776-792
[7] Hirak Kumar Mukhopadhyay Chandi Charan Kandar , Sanjay Kumar Das, Lakshmikanta Ghosh , Bijan Kumar Gupta, *Journal of PharmaSciTech*, 2012, 1(2), 20-26
[8] Jacques Penderis, *BMJ*, 2018, 3-6
[9] Mervyn J Eadie, Peter F Bladin, 2001
[10] http://knowingepilepsy.tripod.com/id9.html
[11] http://www.epilepsy.ca/history-of-epilepsy.html
[12] Sandeep Kumar, Govind Singh, *International Journal of Medical and Health Research*, 2016, 2(10), 32-36
[13] S. Engelborghs, R.D'Hooge, P.P. De Deyn, *Acta neurol. belg.*, 2000, 100, 201-213
[14] Robert S. Fisher, David K. Chen , *Acta Neurologica Taiwanica*, 2006, 15 (4), 225-231
[15] https://www.sharecare.com/health/epilepsy-and-seizures/article/5-treatment-options-for-epilepsy.
[16] Shadab A. Pathan, Zeenat Iqbal, Syed M. A. Zaidi, Sushma Talegaonkar1, Divya Vohra, GauravK. Jain, Adnan Azeem, Nitin Jain, Jigar R. Lalani, Roop K. Khar1 Farhan J. Ahmad, Recent Patents on Drug Delivery & Formulation, 2009, *3*, 71-89
[17] William M. Pardridge, *Advanced Drug Delivery Reviews*, 1335, 15, 5-36
[18] Ho Lun Wong , Xiao Yu Wu , Reina Bendayan, *Advanced Drug Delivery Reviews*, 2002, 64, 686–700
[19] Shinnar, S., Berg, A. T, *Epilepsia*, 1996**,** *37*, 701-708.
[20] Marson, A. G., Kadir, Z. A., Hutton, J. L., Chadwick, D. W., *Epilepsia*, 1997**,** *38*, 859-880.
[21] satinder aneja, suvasini Sharma, *Indian paediatrics*, 2013, 50, 1033-1040.
[22] Bazil, C. W., Pedley, T. A., Annu. *Rev. Med.* 1998**,** *49*, 135-162.
[23] Rogvi-Hansen, B., Gram, L., *Pharmacol. Ther.*, 1995**,** *68*, 425-434.
[24] Leppik, I. E., *Epilepsia*, 2001**,** *42 Suppl 4*, 1-6.
[25] Macleod, S., Appleton, R. E., *Arch. Dis. Child Educ. Pract.* Ed. 2007**,** *92*, 182-188.
[26] Greenwood, R. S., *Epilepsia* 2000**,** *41* (Suppl. 2), S42-S52.
[27] Brodie, M. J., Dichter, M. A., N. Engl. *J. Med*. 1996**,** *334*, 168-175
[28] Schachter, S. C., *Neurotherapeutics* 2007, *4*, 4-11.
[29] Sander, J. W., *Epilepsia*, 2004**,** *45* (Suppl. 6), 28-34
[30] Asconape, J. J., *Semin. Neurol.* 2002, *22*, 27-39.
[31] Johannessen, L. C., Johannessen, S. I., *Drugs*, 2008, *68*, 1925-1939.
[32] Jabir, N.R., Tabrez, S., Ashraf, G.M., Shakil, S., Damanhouri,G.A.. Kamal, M.A.,*Int. J. Nanomed.*, 2012, 7, 4391-4408.
[33] Suntres, Z.E., *J. Toxicol.*, 2011, 2011.
[34] Pathan, S.A., Iqbal, Z., Zaidi, S.M.A., Talegaonkar, S., Vohra, D., Jain, G.K., Azeem, A., Jain, N., Lalani, J.R., Khar, R.K.,Ahmad, F.J., *Recent Pat.Drug Deliv. Formul.*, 2009, 3, (1), 71-89.
[35] Allen, T.M., Hansen, C., Martin, F., Redemann, C., Yau-Young, *Biochim.Biophys. Acta*, 1991, *1066*, (1), 29-36.
[36] Pathan, S.A., Jain, G.K., Akhter, S., Vohora, D., Ahmad, F.J., Khar, R.K, *Drug Discov. today*, 2010, *15*,(17-18), 717-732.
[37] Lu, L., Peter, S.J., D. Lyman, M., Lai, H.-L., Leite, S.M., Tamada, J.A., Uyama, S., Vacanti, J.P., Robert, L., Mikos, A.G., *Biomaterials*, 2000, 21 (18), 1837-1845.

[38] Nasimudeen R. Jabir, Shams Tabrez, C. K. Firoz, Syed Kashif Zaidi, Saleh S. Baeesa, Siew Hua Gan,Shazi Shakil, Mohammad Amjad Kamal:, *Current Drug Metabolism,* 2014, 15,(6) 1-10.
[39] Hyuk, I.M.S., Jeong, U., Xia, Y., *Nat. Mater.* 2005, 4, 671–675.
[40] Friedrich, I., Reichl, S., Muller-Goymann, C.C., *Int. J. Pharm*, 2005, 305, 167–175.
[41] Uner, M., Yener, G., *Int. J. Nanomed.*, 2007, 2 (3), 289-300.
[42] Wissing, S.A., Kayser, O., Müller, R.H., *Adv. Drug Deliv. Rev.*, 2004, *56*, (9), 1257-1272.
[43] Pandey, R., Khuller, G.K., *Tuberculosis (Edinb)*, 2005, *85* (4), 227-234.
[44] Blasi, P., Giovagnoli, S., Schoubben, A., Ricci, M., Rossi, C., *Adv. Drug Deliv. Rev.*, 2007, *59* (6), 454-477.
[45] Dhana Lakshmi, P., Rahul, N., Chakrapani, M., Venkatkrishnakiran, P., *Int. J. Biopharmaceut.*, 2012, *3* (2), 70-77.
[46] López-García, R., Ganem-Rondero, *Journal of Cosmetics, Dermatological Sciences and Applications*,2015, 5, 62-72.
[47] Tausif Alam, Jayamanti Pandit, Divya Vohora, Mohd Aqil, Asgar Ali , Yasmin Sultana, *Expert Opin. Drug Deliv.*, 2014,1-14
[48] Natarajan J, Karri VVSR, Anindita De, *Glob J Nanomed*,1(5),2017,1-6
[49] Azeem, A., Rizwan, M., Ahmad, F.J., Iqbal, Z.; Khar, R.K., Aqil, M., Talegaonkar, S., *AAPS PharmSciTech.*, 2009, *10* (1), 69- 76.
[50] Jain, N., Akhter, S., Jain, G.K., Khan, Z.I., Khar, R.K., Ahmad,F.J., *J. Biomed. Nanotechnol.*, 2011, 7(1), 142-143.
[51] Bhanushali, R.S., Gatne, M.M., Gaikwad, R.V., Bajaj, A.N., Morde, M.A., *Indian J. Pharm. Sci.*, 2009, *71* (6), 707-709.
[52] Shakeel, F., Baboota, S., Ahuja, A., Ali, J., Aqil, M., Shafiq, S., *AAPS PharmSciTech.*, 2007, *8*, (4).
[53] Abu-Elyazid, S.K., Kaseem, A.A., Samy, A.M., Gomaa, M.E., *Asian J. Pharm. Hea. Sci.*, 2011, 1 (3), 99-105.
[54] Sun, X.L., Liu, D.H., Li, P., Xu, W.F., Zhang, N., *J. Chin. Pharm. Sci.*, 2011, *20*, 483-492.
[55] Thakur, N., Garg, G., Sharma, P. K., Kumar, N., *Global J. Pharmacol.*, 2012, *6*(3), 222-225.
[56] Wang, D.-s., Li, J.-g., Li, H.-p., Tang, F.-Q., *Trans. Nonferrous Met. Soc. China*, 2009, 19 (5), 1232- 1236.
[57] Chomoucka, J., Drbohlavova, J., Huska, D., Adam, V., Kizek, R., Hubalek, J., *Pharmacol. Res.*, 2010, 7 (2), 144-149
[58] Tripathi, K,D., Essentials of medical pharmacology ,7th edition
[59] Kumar, R.M., Sameti, M., et al., In: Nalwa, H.S. (Ed.), *Encyclopedia of Nanoscience & Nanotechnology.* American Scientific Publishers, 2003, pp. 1–19.